Leon Chen, Ph.D., is Founder and Managing Partner of Frontline BioVentures. In May 2017, Frontline BioVentures (Frontline) and WuXi Healthcare Ventures (WuXi Ventures) merged to form 6 Dimensions Capital, one of the largest healthcare-focused investment groups with unique capabilities and extensive coverage across China and the United States. Dr. Chen then became 6 Dimensions Capital’s CEO. Before founding Frontline BioVentures in 2012, Dr. Chen was a Partner with Fidelity Growth Partners Asia and a Managing Partner with BioVeda China. Since 2005, Dr. Chen has led a number of investments in the life science sector in China including CITIC Pharmaceuticals, Hile Biopharma, Hua Medicine, Innovent Biologics, Adagene, TenNor Therapeutics, MDDF, Coherent Biopharma, Yikon Genomics, Huazhou, Bio Kangtai, and Neusoft Medical.
Dr. Chen has served as a management consultant and a business adviser to pharmaceutical and biotech companies; past affiliations include McKinsey & Company and Ernst & Young, LLP.
Dr. Chen also worked as a research scientist at Schering-Plough in New Jersey. He was a member of the discovery team of “VYTORIN”/”ZETIA” – now a multibillion dollar drug.
He received a B.S. from Peking University, a Ph.D. with top honors from Catholic University of Leuven, and was a Post-Doctoral Fellow at the Massachusetts Institute of Technology. Dr. Chen holds six issued U.S. patents and co-authored the 14th and 15th Ernst & Young Biotechnology Report.